Castelnau Group (CGL) Competitors

BioPharma Credit (LON:BPCR) and Castelnau Group (LON:CGL) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Which has better earnings & valuation, BPCR or CGL?

BioPharma Credit has higher revenue and earnings than Castelnau Group. Castelnau Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioPharma Credit	£12.99B	0.08	£10.42B	£0.09	10.03
Castelnau Group	£1.95M	131.42	£95.01M	£29.27	2.70

Which has more risk & volatility, BPCR or CGL?

BioPharma Credit has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Castelnau Group has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Does the media favor BPCR or CGL?

In the previous week, BioPharma Credit had 2 more articles in the media than Castelnau Group. MarketBeat recorded 2 mentions for BioPharma Credit and 0 mentions for Castelnau Group. BioPharma Credit's average media sentiment score of 1.13 beat Castelnau Group's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company	Overall Sentiment
BioPharma Credit	Positive
Castelnau Group	Neutral

Do institutionals and insiders have more ownership in BPCR or CGL?

41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 71.2% of Castelnau Group shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by company insiders. Comparatively, 4.7% of Castelnau Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is BPCR or CGL more profitable?

Castelnau Group has a net margin of 4,860.58% compared to BioPharma Credit's net margin of 80.20%. Castelnau Group's return on equity of 34.01% beat BioPharma Credit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioPharma Credit	80.20%	8.51%	4.98%
Castelnau Group	4,860.58%	34.01%	-0.50%

Summary

BioPharma Credit beats Castelnau Group on 8 of the 13 factors compared between the two stocks.